COGNITION THERAPEUTICS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
COGNITION THERAPEUTICS INC. - More news...
COGNITION THERAPEUTICS INC. - More news...
- Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches
- Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences
- Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC
- Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease
- Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
- Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer
- Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023
- Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases
- Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes
- Cognition Therapeutics Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies
- Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
- Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023
- UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
- Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
- Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD
- Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference
- Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease
- Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia
- Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
- Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease
- Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"
- First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812
- Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
- Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD
- Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series
- Cognition Therapeutics Announces Closing of Public Offering
- Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
- Cognition Therapeutics Announces Pricing of Public Offering
- Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.
- Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development